Letters to the Editors
Sorafenib-induced erythema annulare centrifugum with spontaneous resolution after skin biopsy
First published: 20 July 2017
No abstract is available for this article.
References
- 1Wilhelm SM, Adnane L, Newell P et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol. Cancer Ther. 2008; 7: 3129.
- 2Mclellan B, Kerr H. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib. Dermatol. Ther. 2011; 24: 396–400.
- 3Lewin J, Farley-Loftus R, Pomeranz MK. Erythema multiforme-like drug reaction to sorafenib. J. Drugs Dermatol. 2011; 10: 1462–3.
- 4Rübsam K, Flaig MJ, Ruzicka T et al. Erythema marginatum hemorrhagicum: a unique cutaneous side effect of sorafenib. J. Am. Acad. Dermatol. 2011; 64: 1194–6.
- 5Levin NA, Patterson JW, Luke LY et al. Resolution of patch-type granuloma annulare lesions after biopsy. J. Am. Acad. Dermatol. 2002; 46: 426–9.
